Business Wire

TAKEDA-PHARMACEUTICAL

Share
Takeda Announces Its Certification in Select Group of Global Top Employers® 2018

Takeda Pharmaceutical Company Limited (TOKYO: 4502 ), (“Takeda”) today announced it has become part of a select group of only thirteen (13) companies and one of two pharmaceuticals to receive global Top Employer® status for 2018. Established over 25 years ago, award certification is given annually by the Top Employers Institute to companies with exceptional employee offerings. The program is organized and designed by the Institute to recognize those that create optimal conditions for their employees to develop professionally and personally, and that achieve the highest standards of excellence for their people.

To be certified globally at least 20 countries, four regions and the applicant company’s global headquarters all needed to be certified by the Top Employer Institute, which Takeda has achieved this year.

“We’d like to thank the Top Employers Institute for recognizing Takeda for the corporate culture we have created,” commented David Osborne, Takeda’s Global Human Resources Officer. “Our focus on patients, combined with our values to act with Integrity, Fairness, Honesty and Perseverance, create a dynamic environment that our people feel strongly about and in which they are empowered to shine.”

The Top Employers Institute assesses company offerings to their employees. It covers 600 HR practices across the following areas:

  • Talent Strategy
  • Workforce Planning
  • On-boarding
  • Learning & Development
  • Performance Management
  • Leadership Development
  • Career & Succession Management
  • Compensation & Benefits
  • Culture

“Takeda really stands out as a global Top Employer for its commitment to people development,” said David Plink, CEO of the Top Employers Institute. “The learning opportunities provided, which enhance the employee journey and are centered on enabling employees to reach their personal professional goals, are first-class and a real differentiator.”

Takeda met the tough requirements of the Top Employers Institute, receiving accreditation in more than 20 countries and regions, across four geographic areas, namely:

  • Asia Pacific: Australia, China, Hong Kong, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan and Thailand
  • Europe: Ireland, Russia, Spain, Turkey and Ukraine
  • Latin America: Argentina, Brazil, Colombia, Ecuador, Mexico, Peru and Venezuela
  • North America: Canada and United States
  • South Africa

“At Takeda, we are passionate about providing the right environment so our people can learn and progress their careers,” said David Osborne. “We endeavor to provide diverse learning opportunities across more than 70 countries through programs at institutions such as Oxford University, Massachusetts Institute of Technology (MIT), Wharton and INSEAD, as well as by establishing mentoring relationships with our most senior leaders.”
To learn more about the Top Employers Institute and the Top Employers certification visit http://www.top-employers.com .

About Takeda

Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas, plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries. For more information, visit https://www.takeda.com/newsroom/ .

Takeda’s Values & People

Takeda is building a patient-centric and customer-centric organization based on Our Values; always act upon Takeda-ism (Integrity, Fairness, Honesty and Perseverance) and do everything in the order of the four priorities of Patient-Trust-Reputation-Business . We put the patients first and foremost, and through that, we build trust with society, which solidifies our reputation, and that finally can lead to our business performance. These are deeply ingrained in our ways of working. They ensure our commitment to quality and that we do the right thing - at all times.

Our local organizations and people are empowered to respond in the best way to customer needs, and have the possibility to develop and thrive in a diverse and agile organization.

Takeda leaders demonstrate strategic thinking, find innovative ways to serve patients, build trust with society, reinforce our reputation, and grow the business. They create an environment that inspires and enables people to collaborate and move the organization forward. They focus on our few designated priorities and deliver superior results. And they elevate the capabilities of our organization now and for the future.

Takeda: Empowering Our People to Shine

Working at Takeda, it is important that our people feel empowered to perform to the very best of their ability as they work towards creating a brighter future for millions of patients worldwide. We enable all our people to grow, providing support and training where needed, and fostering a culture of trust to allow leadership at all levels.

Contact:

Media contacts
Media outside Japan:
Takeda Pharmaceutical Company Limited
Vince Docherty, +65 8332 4233
vince.docherty@takeda.com
Takeda Pharmaceutical Company Limited
Rebecca Northridge, +65 9457 6037
rebecca.northridge@takeda.com
Japanese Media:
Takeda Pharmaceutical Company Limited
Kazumi Kobayashi, +81 3 3278 2095
kazumi.kobayashi@takeda.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release

- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P

Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release

With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp

Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release

The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev

7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release

MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t

First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release

Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye